Increased level of basophil CD203c expression predicts severe chronic urticaria

Journal of Korean Medical Science

Volumn 29, Issue 1, 2014, Pages 43-47

  Ye, Young Min ^a   Yang, Eun Mi ^a   Yoo, Hye Soo ^a   Shin, Yoo Seob ^a   Kim, Seung Hyun ^a   Park, Hae Sim ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Basophil activation; CD203c Protein; Chronic urticaria; Human

Indexed keywords

ANTI THYROGLOBULIN; AUTOANTIBODY; ENPP3 PROTEIN, HUMAN; FCEPSILONRI ALPHA CHAIN, HUMAN; FCEPSILONRI ALPHA-CHAIN, HUMAN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; INORGANIC PYROPHOSPHATASE; PHOSPHODIESTERASE;

ADULT; ANTI-THYROGLOBULIN; ARTICLE; BASOPHIL; BASOPHIL ACTIVATION; BIOSYNTHESIS; BLOOD; CD203C PROTEIN, HUMAN; CHRONIC URTICARIA; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; MALE; URTICARIA;

BASOPHIL ACTIVATION; CD203C PROTEIN, HUMAN; CHRONIC URTICARIA;

ADULT; AUTOANTIBODIES; BASOPHILS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN E; MALE; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES; RECEPTORS, IGE; URTICARIA;

EID: 84907424463     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.1.43     Document Type: Article

References (27)

1. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, Grattan CE, Kapp A, Maurer M, Merk HF, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427-43.
2. Morgan M, Khan DA. Therapeutic alternatives for chronic urticaria: an evidence-based review, part 1. Ann Allergy Asthma Immunol 2008; 100: 403-11.
3. Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res 2012; 4: 326-31.
4. Grattan CE, O'Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT, Kobza Black A, Greaves MW. Randomized double-blind study of cyclo-sporin in chronic 'idiopathic' urticaria. Br J Dermatol 2000; 143: 365-72.
5. Nam YH, Kim JH, Jin HJ, Hwang EK, Shin YS, Ye YM, Park HS. Effects of omalizumab treatment in patients with refractory chronic urticaria. Al-lergy Asthma Immunol Res 2012; 4: 357-61.
6. Kessel A, Bishara R, Amital A, Bamberger E, Sabo E, Grushko G, Toubi E. Increased plasma levels of matrix metalloproteinase-9 are associated with the severity of chronic urticaria. Clin Exp Allergy 2005; 35: 221-5.
7. Kasperska-Zajac A, Sztylc J, Machura E, Jop G. Plasma IL-6 concentra-tion correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients. Clin Exp Allergy 2011; 41: 1386-91.
8. Tedeschi A, Lorini M, Suli C, Asero R. Serum interleukin-18 in patients with chronic ordinary urticaria: association with disease activity. Clin Exp Dermatol 2007; 32: 568-70.
9. Triwongwaranat D, Kulthanan K, Chularojanamontri L, Pinkaew S. Cor-relation between plasma D-dimer levels and the severity of patients with chronic urticaria. Asia Pac Allergy 2013; 3: 100-5.
10. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau A, Grattan CE, Kapp A, Merk HF, Rogala B, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1417-26.
11. Falcone FH, Knol EF, Gibbs BF. The role of basophils in the pathogenesis of allergic disease. Clin Exp Allergy 2011; 41: 939-47.
12. Grattan CE, Dawn G, Gibbs S, Francis DM. Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, in-fluence of loratadine and prednisolone and relationship to disease activ-ity. Clin Exp Allergy 2003; 33: 337-41.
13. Ito Y, Satoh T, Takayama K, Miyagishi C, Walls AF, Yokozeki H. Basophil recruitment and activation in inflammatory skin diseases. Allergy 2011; 66: 1107-13.
14. Lourenço FD, Azor MH, Santos JC, Prearo E, Maruta CW, Rivitti EA, Duarte AJ, Sato MN. Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of hista-mine release induced by anti-IgE stimulus. Br J Dermatol 2008; 158: 979-86.
15. Asero R, Lorini M, Chong SU, Zuberbier T, Tedeschi A. Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells. Clin Exp Allergy 2004; 34: 1111-4.
16. Gentinetta T, Pecaric-Petkovic T, Wan D, Falcone FH, Dahinden CA, Pichler WJ, Hausmann OV. Individual IL-3 priming is crucial for consis-tent in vitro activation of donor basophils in patients with chronic urti-caria. J Allergy Clin Immunol 2011; 128: 1227-34.e5.
17. Chirumbolo S. Basophil activation test in allergy: time for an update? Int Arch Allergy Immunol 2012; 158: 99-114.
18. Boumiza R, Monneret G, Forissier MF, Savoye J, Gutowski MC, Powell WS, Bienvenu J. Marked improvement of the basophil activation test by detecting CD203c instead of CD63. Clin Exp Allergy 2003; 33: 259-65.
19. Chinuki Y, Kaneko S, Dekio I, Takahashi H, Tokuda R, Nagao M, Fujisa-wa T, Morita E. CD203c expression-based basophil activation test for di-agnosis of wheat-dependent exercise-induced anaphylaxis. J Allergy Clin Immunol 2012; 129: 1404-6.
20. Eckman JA, Hamilton RG, Gober LM, Sterba PM, Saini SS. Basophil phe-notypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies. J Invest Dermatol 2008; 128: 1956-63.
21. Yasnowsky KM, Dreskin SC, Efaw B, Schoen D, Vedanthan PK, Alam R, Harbeck RJ. Chronic urticaria sera increase basophil CD203c expression. J Allergy Clin Immunol 2006; 117: 1430-4.
22. Vasagar K, Vonakis BM, Gober LM, Viksman A, Gibbons SP Jr, Saini SS. Evidence of in vivo basophil activation in chronic idiopathic urticaria. Clin Exp Allergy 2006; 36: 770-6.
23. Ye YM, Park JW, Kim SH, Choi JH, Hur GY, Lee HY, Lee EH, Park HS. Clinical evaluation of the computerized chronic urticaria-specific quali-ty of life questionnaire in Korean patients with chronic urticaria. Clin Exp Dermatol 2012; 37: 722-8.
24. Saini SS, MacGlashan D. How IgE upregulates the allergic response. Curr Opin Immunol 2002; 14: 694-7.
25. Schroeder JT, Chichester KL, Bieneman AP. Human basophils secrete IL-3: evidence of autocrine priming for phenotypic and functional responses in allergic disease. J Immunol 2009; 182: 2432-8.
26. Gernez Y, Tirouvanziam R, Yu G, Ghosn EE, Reshamwala N, Nguyen T, Tsai M, Galli SJ, Herzenberg LA, Herzenberg LA, et al. Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergy. Int Arch Allergy Immunol 2011; 154: 318-27.
27. Bühring HJ, Streble A, Valent P. The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol 2004; 133: 317-29.